ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 72.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 49,643 shares of the specialty pharmaceutical company's stock after selling 132,385 shares during the period. Nuveen Asset Management LLC owned approximately 0.24% of ANI Pharmaceuticals worth $2,744,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ANIP. Millennium Management LLC increased its position in ANI Pharmaceuticals by 89.3% during the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock worth $55,437,000 after purchasing an additional 473,097 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of ANI Pharmaceuticals by 4.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock worth $37,906,000 after buying an additional 30,420 shares during the period. Deep Track Capital LP increased its position in shares of ANI Pharmaceuticals by 28.6% during the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock worth $35,879,000 after buying an additional 144,214 shares during the period. Global Alpha Capital Management Ltd. increased its position in shares of ANI Pharmaceuticals by 16.4% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock worth $34,525,000 after buying an additional 88,100 shares during the period. Finally, William Blair Investment Management LLC boosted its stake in ANI Pharmaceuticals by 2.2% during the fourth quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock worth $26,826,000 after acquiring an additional 10,440 shares in the last quarter. Institutional investors own 76.05% of the company's stock.

Insider Activity

In related news, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the completion of the transaction, the senior vice president now directly owns 89,897 shares in the company, valued at $5,400,112.79. The trade was a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now owns 80,545 shares of the company's stock, valued at $5,100,914.85. This represents a 0.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,681 shares of company stock worth $408,498. Corporate insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Trading Down 1.3%

Shares of ANI Pharmaceuticals stock traded down $0.79 during trading on Wednesday, hitting $60.87. The stock had a trading volume of 307,309 shares, compared to its average volume of 307,718. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $77.00. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm's fifty day simple moving average is $65.57 and its 200-day simple moving average is $60.80. The stock has a market cap of $1.32 billion, a PE ratio of -110.67 and a beta of 0.56.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. The firm had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business's revenue was up 43.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.82 earnings per share. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ANIP. Truist Financial upped their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a report on Monday, April 21st. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target on the stock. Guggenheim reiterated a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 price target on the stock. Finally, Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $80.13.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.